Time-Course of Contrast Enhancement in Spleen and Liver with Exia 160, Fenestra LC, and VC

Willekens, Inneke; Lahoutte, Tony; Buls, Nico; Vanhove, Christian; Deklerck, Rudi; Bossuyt, Axel; Mey, Johan De

doi:10.1007/s11307-008-0186-8

Cited by 59 publications

(63 citation statements)

References 27 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most currently commercially available MicroCT contrasts can be generally subdivided into particulate non-metabolizable macrophage specific and polydisperse metabolizable iodine-based contrasts 23,[33][34][35][36] . Although particulate agents offer greater X-ray opacification due to their higher atomic number (barium, Z=56; and gold, Z=79), they cannot be used for metabolic assessment.…”

Section: Discussionmentioning

confidence: 99%

<em>In Vivo</em> Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Deel

Ridwan

Vliet

et al. 2016

JoVE

View full text Add to dashboard Cite

The use of Micro-Computed Tomography (MicroCT) for in vivo studies of small animals as models of human disease has risen tremendously due to the fact that MicroCT provides quantitative high-resolution three-dimensional (3D) anatomical data non-destructively and longitudinally. Most importantly, with the development of a novel preclinical iodinated contrast agent called eXIA160, functional and metabolic assessment of the heart became possible. However, prior to the advent of commercial MicroCT scanners equipped with X-ray flat-panel detector technology and easy-to-use cardio-respiratory gating, preclinical studies of cardiovascular disease (CVD) in small animals required a MicroCT technologist with advanced skills, and thus were impractical for widespread implementation. The goal of this work is to provide a practical guide to the use of the high-speed Quantum FX MicroCT system for comprehensive determination of myocardial global and regional function along with assessment of myocardial perfusion, metabolism and viability in healthy mice and in a cardiac ischemia mouse model induced by permanent occlusion of the left anterior descending coronary artery (LAD).

show abstract

Section: Discussionmentioning

confidence: 99%

<em>In Vivo</em> Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Deel

Ridwan

Vliet

et al. 2016

JoVE

View full text Add to dashboard Cite

show abstract

“…Fifteen minutes after the administration of 0.015 ml/gram Fenestra VC-131 ® through the tail vein with a bolus injection, the animals were anesthetized with an 8 !L/gram IP injection of a mixture of 1.05 ml ketamine (Ketamine 1000, CEVA Santé Animale, Brussel, Belgium), 0.3 ml xylazine (Xyl-M 2 %, VMD, Arendonk, Belgium) and 3.4 ml physiological fluid. The animals were scanned after 10 minutes of anaesthesia, as optimal contrast is achieved 25 minutes after administering Fenestra ® [14]. The 25 minute total waiting time also reduced the chances on spasms and other irregularities affecting imaging quality.…”

Section: Methodsmentioning

confidence: 99%

Replacing Vascular Corrosion Casting by In Vivo Micro-CT Imaging for Building 3D Cardiovascular Models in Mice

et al. 2010

View full text Add to dashboard Cite

Purpose:The purpose of this study was to investigate if in vivo micro-CT is a reliable alternative to micro-CT scanning of a vascular corrosion cast. This would allow to study the early development of cardiovascular diseases. Procedures: Datasets using both modalities were acquired, segmented and used to generate a 3D geometrical model from 9 mice. As blood-pool contrast agent Fenestra VC-131 was used. Batson's No. 17 was used as casting agent. CFD simulations were performed on both datasets to quantify the difference in wall shear stress (WSS). Results: Aortic arch diameters show 30 to 40% difference between the Fenestra VC-131 and the casted dataset. The aortic arch bifurcation angles show less than 20% difference between both datasets. Numerically computed WSS showed a 28% difference between both datasets. Conclusions: Our results indicate that in vivo micro-CT imaging can provide an excellent alternative for vascular corrosion casting. This enables follow-up studies.

show abstract

“…For contrast CT, eXIA 160-XL (Binitio Biomedical Inc.) was administered via the tail vein at a dosage of 0.2-0.4 mL (160 mg of iodine per milliliter). To optimize the spleen contrast, CT images of the abdomen were obtained repeatedly at intervals ranging between 15 min and 2 h after eXIA 160-XL injection (15).…”

Section: Ctmentioning

confidence: 99%

“…After a 24-h recovery period, the rat was positioned in the PET/CT scanner and administered the contrast reagent eXIA 160-XL (0.4 mL) via the tail vein. Abdominal CT was first performed for 30 min to delineate the spleen (15). The rat was subsequently administered 18 F-fallypride (32 MBq) by tail vein injection and then imaged for 2 h in the PET scanner.…”

Section: Islet Transplantationmentioning

confidence: 99%

¹⁸F-Fallypride PET of Pancreatic Islets: In Vitro and In Vivo Rodent Studies

Garcia¹,

Mirbolooki²,

Constantinescu³

et al. 2011

J Nucl Med

View full text Add to dashboard Cite

Islet cell loss in the pancreas results in diabetes. A noninvasive method that measures islet cell loss and also tracks the fate of transplanted islets would facilitate the development of novel therapeutics and improve the management of diabetes. We describe a novel dopamine D 2 /D 3 receptor (D 2 /D 3 R)-based PET method to study islet cells in the rat pancreas and in islet cell transplantation. Methods: 18 F-fallypride binding to isolated rat islets and pancreas was evaluated in the absence and presence of the D 2 /D 3 R inhibitor haloperidol. After intravenous 18 F-fallypride (28-37 MBq) administration, normal rats and rats pretreated with haloperidol were imaged in a PET/CT scanner and subsequently studied ex vivo for 18 F-fallypride localization in the pancreas. A streptozotocin-treated diabetic rat model was used to study localization of 18 F-fallypride in the pancreas, in vitro and ex vivo. Rat islet cells were transplanted into the spleen and visualized using 18 F-fallypride PET. Results: 18 Ffallypride bound to isolated islet cells and pancreatic sections with an endocrine or exocrine selectivity of approximately 4; selectivity was reduced by haloperidol, suggesting that binding was D 2 /D 3 R-specific. Chemical destruction of islets by streptozotocin decreased 18 F-fallypride binding in pancreas by greater than 50%, paralleling the decrease in insulin immunostaining. Uptake of 18 F-fallypride in the pancreas was confirmed by radiochromatography and was 0.05% injected dose/cm 3 as measured by PET/CT. The ratio of 18 F-fallypride uptake in the pancreas to reference tissue (erector spinae muscle) was 5.5. Rat islets transplanted into the spleen were visualized in vivo by 18 F-fallypride and confirmed by immunostaining. The ratio of spleen-transplanted islets to erector spinae muscle was greater than 5, compared with a ratio of 2.8 in untransplanted rats.Conclusion: These studies demonstrate the potential utility of 18 F-fallypride as a PET agent for islet cells.

show abstract

Time-Course of Contrast Enhancement in Spleen and Liver with Exia 160, Fenestra LC, and VC

Abstract: Exia 160 allows rapid spleen and liver enhancement. The high iodine content results in small injection volumes.

Cited by 59 publications

References 27 publications

<em>In Vivo</em> Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

<em>In Vivo</em> Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Replacing Vascular Corrosion Casting by In Vivo Micro-CT Imaging for Building 3D Cardiovascular Models in Mice

¹⁸F-Fallypride PET of Pancreatic Islets: In Vitro and In Vivo Rodent Studies

Contact Info

Product

Resources

About

Time-Course of Contrast Enhancement in Spleen and Liver with Exia 160, Fenestra LC, and VC

Abstract: Exia 160 allows rapid spleen and liver enhancement. The high iodine content results in small injection volumes.

Cited by 59 publications

References 27 publications

<em>In Vivo</em> Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

<em>In Vivo</em> Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Replacing Vascular Corrosion Casting by In Vivo Micro-CT Imaging for Building 3D Cardiovascular Models in Mice

18F-Fallypride PET of Pancreatic Islets: In Vitro and In Vivo Rodent Studies

Contact Info

Product

Resources

About

¹⁸F-Fallypride PET of Pancreatic Islets: In Vitro and In Vivo Rodent Studies